BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23924788)

  • 21. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process.
    Mauri C; Mars LT; Londei M
    Nat Med; 2000 Jun; 6(6):673-9. PubMed ID: 10835684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
    Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
    Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
    Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD
    Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-VEGF antibody enhances the antitumor effect of CD40.
    Selvaraj S; Raundhal M; Patidar A; Saha B
    Int J Cancer; 2014 Oct; 135(8):1983-8. PubMed ID: 24604357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies.
    Ito D; Ogasawara K; Matsushita K; Morohashi T; Namba K; Matsuki N; Kitaichi N; Inuyama Y; Hosokawa M; Nakayama E; Iwabuchi K; Onoé K
    Immunobiology; 2000 Apr; 201(5):527-40. PubMed ID: 10834311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model.
    Hunter TB; Alsarraj M; Gladue RP; Bedian V; Antonia SJ
    Scand J Immunol; 2007 May; 65(5):479-86. PubMed ID: 17444959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
    French RR; Chan HT; Tutt AL; Glennie MJ
    Nat Med; 1999 May; 5(5):548-53. PubMed ID: 10229232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eradication of established tumors in mice by a combination antibody-based therapy.
    Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
    Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.
    Wei H; Wang H; Lu B; Li B; Hou S; Qian W; Fan K; Dai J; Zhao J; Guo Y
    Cancer Res; 2008 May; 68(10):3854-62. PubMed ID: 18483270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells.
    Bergstrom RT; Silverman DA; Chambers K; Kim JA
    Otolaryngol Head Neck Surg; 2004 Jan; 130(1):94-103. PubMed ID: 14726917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
    Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM
    Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells.
    Dubrot J; Portero A; Orive G; Hernández RM; Palazón A; Rouzaut A; Perez-Gracia JL; Hervás-Stubbs S; Pedraz JL; Melero I
    Cancer Immunol Immunother; 2010 Nov; 59(11):1621-31. PubMed ID: 20607237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
    Liu A; Hu P; Khawli LA; Epstein AL
    J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-12 induces an effective antitumor response in malignant mesothelioma.
    Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Scott B; Robinson BW
    Am J Respir Cell Mol Biol; 1998 Nov; 19(5):738-46. PubMed ID: 9806738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.